Roche has revealed new phase 2 data with enicepatide (formerly CT-388), its potential rival to Eli Lilly's dual GIP/GLP-1 ...

The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...

Dazodalibep is one of the assets included in Amgen's near-$28 billion takeover of Horizon Pharma in 2023, which also gave it ...

Citing former Italian prime Minister and economist Mario Draghi, the company leaders have urged the EU and national governments in Europe to counter the 'slow agony' of decline facing strategic ...

The UK's National Institute for Health and Care Research (NIHR) has revealed the first round of funding for an initiative that aims to bridge the gap between early-stage medical discoveries and ...

Everyone agrees that AI is changing pharmacovigilance. But the nature of that change is evolving. The first wave of AI deployment in pharmacovigilance focused on automating repetitive tasks, but the ...

Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical ...

UK Prime Minister Andy Burnham, who lost his father to Alzheimer's disease last week, has been urged to implement a ...

Iambic Therapeutics, which specialises in applying AI to drug discovery and development, has filed for an IPO on the Nasdaq, shortly after adding AbbVie to its roster of pharma pa ...

An adjuvanted, trivalent influenza vaccine developed by CSL Seqirus and recently approved in the UK, Aujemflu, will be deployed ahead of the 2027/28 flu season under an agreement with the government.

A consumer advocacy group has scrutinised some of the Most Favoured Nation (MFN) pricing deals the Trump administration has ...

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience in a deal valued at $470 million. The $8-per-share deal will ...